| Nome |
# |
|
A decisional algorithm to start iron chelation in patients with beta thalassemia, file e2f56ed3-c51f-3eaf-e053-3a05fe0a5d97
|
355
|
|
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders, file e2f56ed5-7939-3eaf-e053-3a05fe0a5d97
|
174
|
|
No evidence of cardiac iron in 20 never or minimally transfused patients with thalassemia intermedia, file e2f56ed5-7c5e-3eaf-e053-3a05fe0a5d97
|
122
|
|
Pregnancy and β-thalassemia: An Italian multicenter experience, file e2f56ed5-78e6-3eaf-e053-3a05fe0a5d97
|
113
|
|
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up, file e2f56ed5-7777-3eaf-e053-3a05fe0a5d97
|
110
|
|
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study, file e2f56ed9-e20f-3eaf-e053-3a05fe0a5d97
|
94
|
|
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021, file ee0d7c62-9066-4d58-8d5d-5c95cd08d812
|
80
|
|
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias, file e2f56eda-246c-3eaf-e053-3a05fe0a5d97
|
79
|
|
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations, file e2f56ed9-d0e0-3eaf-e053-3a05fe0a5d97
|
54
|
|
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study, file e2f56ed9-f514-3eaf-e053-3a05fe0a5d97
|
53
|
|
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia, file e2f56ed9-fc17-3eaf-e053-3a05fe0a5d97
|
48
|
|
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia, file e2f56ed5-77dc-3eaf-e053-3a05fe0a5d97
|
44
|
|
Pregnancy in Thalassemia, file e2f56ed9-e20e-3eaf-e053-3a05fe0a5d97
|
44
|
|
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias, file e2f56ed9-f9ea-3eaf-e053-3a05fe0a5d97
|
44
|
|
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis, file e2f56ed9-df05-3eaf-e053-3a05fe0a5d97
|
43
|
|
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study, file e2f56ed9-df13-3eaf-e053-3a05fe0a5d97
|
43
|
|
Beta-thalassemia, file e2f56ed5-7927-3eaf-e053-3a05fe0a5d97
|
40
|
|
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS), file e2f56eda-b9b9-3eaf-e053-3a05fe0a5d97
|
39
|
|
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies", file 04bcbb3f-b3d9-4887-aeb6-85102ead79aa
|
38
|
|
Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies, file e2f56eda-ba18-3eaf-e053-3a05fe0a5d97
|
25
|
|
Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending, file 44d7b408-63ed-4814-aec3-6ff003a46b04
|
19
|
|
Selecting β-thalassemia Patients for Gene Therapy: A Decision-making Algorithm, file e2f56eda-d8d9-3eaf-e053-3a05fe0a5d97
|
17
|
|
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload, file e2f56eda-a251-3eaf-e053-3a05fe0a5d97
|
16
|
|
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort, file e2f56ed9-bb5e-3eaf-e053-3a05fe0a5d97
|
12
|
|
Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy, file e2f56eda-a03a-3eaf-e053-3a05fe0a5d97
|
12
|
|
The Management of Endocrine Complications in Patients with Haemoglobinopathies: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE), file d793dd95-68d0-4ddd-8266-7a4d9b3068b1
|
11
|
|
Genetic basis, pathophysiology and diagnosis, file e2f56ed5-777d-3eaf-e053-3a05fe0a5d97
|
9
|
|
Phenoconversion’ in adult patients with β-thalassemia, file 49a2ba3b-0807-4c3d-961d-7366857601d4
|
8
|
|
Pretransfusion hemoglobin level and mortality in adults with transfusiondependent β-thalassemia, file 20c06347-3b2f-454d-8396-6196a582784c
|
7
|
|
null, file e2f56ed6-d466-3eaf-e053-3a05fe0a5d97
|
6
|
|
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study, file e2f56ed7-8207-3eaf-e053-3a05fe0a5d97
|
6
|
|
Changing patterns of thalassaemia in Italy: a WebThal perspective., file e2f56ed9-fac3-3eaf-e053-3a05fe0a5d97
|
5
|
|
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia, file e2f56ed9-fc15-3eaf-e053-3a05fe0a5d97
|
5
|
|
Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence, file 276a0a25-b842-45a5-a8ad-0c6025871dca
|
4
|
|
A genetic score for the prediction of beta-thalassemia severity, file e2f56ed4-6654-3eaf-e053-3a05fe0a5d97
|
4
|
|
Deferasirox and children: From clinical trials to the real world, file e2f56ed5-83d2-3eaf-e053-3a05fe0a5d97
|
4
|
|
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders, file e2f56ed5-90b6-3eaf-e053-3a05fe0a5d97
|
4
|
|
Management of the Sickle Cell Trait: An Opinion by Expert Panel Members., file a679c130-c366-4d85-bcfa-8a8000cd3c16
|
3
|
|
Nephrological Complications in Hemoglobinopathies: SITE Good Practice, file dec1c686-a633-4272-8e17-7c782efbc6f1
|
3
|
|
Thalassemia major between liver and heart: Where we are now, file e2f56ed5-83b4-3eaf-e053-3a05fe0a5d97
|
3
|
|
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders, file e2f56ed5-8726-3eaf-e053-3a05fe0a5d97
|
3
|
|
Current growth patterns in children and adolescents with thalassemia major, file e2f56ed5-8b65-3eaf-e053-3a05fe0a5d97
|
3
|
|
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies", file ecfaaf32-a303-4ad6-ab93-8a1e7abaed45
|
3
|
|
Investigating the Alpha 1Ncol mutation, file e2f56ed4-fd8f-3eaf-e053-3a05fe0a5d97
|
2
|
|
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects, file e2f56ed5-8161-3eaf-e053-3a05fe0a5d97
|
2
|
|
Cholelithiasis in thalassemia major, file e2f56ed5-8235-3eaf-e053-3a05fe0a5d97
|
2
|
|
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia., file e2f56ed6-a13c-3eaf-e053-3a05fe0a5d97
|
2
|
|
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia, file e2f56ed7-e43d-3eaf-e053-3a05fe0a5d97
|
2
|
|
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015, file e2f56ed7-e5f3-3eaf-e053-3a05fe0a5d97
|
2
|
|
Hematological phenotypes in children according to the α-globin genotypes, file e2f56ed7-ed0f-3eaf-e053-3a05fe0a5d97
|
2
|
|
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial, file e2f56eda-8263-3eaf-e053-3a05fe0a5d97
|
2
|
|
Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-Thalassemia, file e2f56eda-a03c-3eaf-e053-3a05fe0a5d97
|
2
|
|
null, file e2f56ed3-94b0-3eaf-e053-3a05fe0a5d97
|
1
|
|
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study, file e2f56ed5-76bb-3eaf-e053-3a05fe0a5d97
|
1
|
|
Pathophysiology of beta thalassaemia, file e2f56ed5-792a-3eaf-e053-3a05fe0a5d97
|
1
|
|
Thalassemia major: who is afraid of serum ferritin below 500 μg/l?, file e2f56ed5-7a96-3eaf-e053-3a05fe0a5d97
|
1
|
|
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia, file e2f56ed5-7b7c-3eaf-e053-3a05fe0a5d97
|
1
|
|
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5], file e2f56ed5-7c64-3eaf-e053-3a05fe0a5d97
|
1
|
|
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox, file e2f56ed5-80b2-3eaf-e053-3a05fe0a5d97
|
1
|
|
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment, file e2f56ed5-8163-3eaf-e053-3a05fe0a5d97
|
1
|
|
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up, file e2f56ed5-816e-3eaf-e053-3a05fe0a5d97
|
1
|
|
A complicated disease: What can be done to manage thalassemia major more effectively?, file e2f56ed5-81d5-3eaf-e053-3a05fe0a5d97
|
1
|
|
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload, file e2f56ed5-824d-3eaf-e053-3a05fe0a5d97
|
1
|
|
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias, file e2f56ed5-828a-3eaf-e053-3a05fe0a5d97
|
1
|
|
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major, file e2f56ed5-8346-3eaf-e053-3a05fe0a5d97
|
1
|
|
Natural history of hepatitis C in thalassemia major: a long-term prospective study, file e2f56ed5-83c6-3eaf-e053-3a05fe0a5d97
|
1
|
|
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia, file e2f56ed5-8583-3eaf-e053-3a05fe0a5d97
|
1
|
|
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major, file e2f56ed5-86e0-3eaf-e053-3a05fe0a5d97
|
1
|
|
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia, file e2f56ed5-87d2-3eaf-e053-3a05fe0a5d97
|
1
|
|
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia, file e2f56ed5-8982-3eaf-e053-3a05fe0a5d97
|
1
|
|
Alpha-Thalassemia, file e2f56ed5-8b46-3eaf-e053-3a05fe0a5d97
|
1
|
|
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION), file e2f56ed5-8c16-3eaf-e053-3a05fe0a5d97
|
1
|
|
Prospettive in Pediatria, file e2f56ed5-8dc9-3eaf-e053-3a05fe0a5d97
|
1
|
|
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron, file e2f56ed5-8e05-3eaf-e053-3a05fe0a5d97
|
1
|
|
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major, file e2f56ed5-9011-3eaf-e053-3a05fe0a5d97
|
1
|
|
Deferasirox: pharmacokinetics and clinical experience, file e2f56ed5-9d39-3eaf-e053-3a05fe0a5d97
|
1
|
|
β-Thalassemia, file e2f56ed5-c2ea-3eaf-e053-3a05fe0a5d97
|
1
|
|
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation, file e2f56ed6-8593-3eaf-e053-3a05fe0a5d97
|
1
|
|
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies, file e2f56ed9-bdf0-3eaf-e053-3a05fe0a5d97
|
1
|
|
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major, file e2f56ed9-dfe6-3eaf-e053-3a05fe0a5d97
|
1
|
|
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited, file e2f56ed9-f79f-3eaf-e053-3a05fe0a5d97
|
1
|
|
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization, file e2f56eda-bcc7-3eaf-e053-3a05fe0a5d97
|
1
|
| Totale |
1.857 |